Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance

Association of Antibiotic Measures and Control of Bacterial Resistance

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01788449

Enrollment

335

Registered

2013-02-11

Start date

2005-05-31

Completion date

2007-02-28

Last updated

2013-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Infections

Keywords

Antibiotic Bacterial Resistance

Brief summary

Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of bacteria.

Detailed description

Primarily, this study is designed to assess the efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of extended-spectrum betalactamases (ESBLs) producing E.coli or K pneumoniae, S aureus methicillin resistant (MRSA) and Enterococcus vancomycin resistant (VRE). Secondly, this study plans to determine the acquisition rate of ESBL producing E Coli or K pneumoniae, methicillin resistant S Aureus (MRSA) and vancomycin resistant Enterococcus spp (VRE), both pre- and post-intervention.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

All patients admitted in ICU will be enrolled (who qualify for treatment).

Design outcomes

Primary

Measure	Time frame
Endpoints will be efficacy of piperacillin/tazobactam in reducing colonization rates and infection of E coli or K pneumoniae, vancomycin resistant enterococcus and methicillin resistant S aureus	8 months

Secondary

Measure	Time frame
Endpoints will be acquisition and infection rate of ESBL producing E coli or K pneumoniae, vancomycin resistant enterococcus and methicillin resistant S aureus	8 months

Outcome results